Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial
Description
CONCLUSION: HIC after AHF was safe and resulted in a significant reduction of all-cause death or HF-readmission at 180 days across the study age spectrum. Older patients have smaller benefits in terms of quality of life. This article is protected by
